Asterias Biotherapeutics, Inc. (AST)

[tradetrak]

Geez. 'Bout time. But, wow, really positive results from the initial cohort. Supposed to only be measuring safety but had an improvement in 2//3 (?) of the cohort typically only experienced by 5% of patients. Very small sample but still, we're at the lowest dose.